Abstract
A 53-year-old man with a 22-year history of ulcerative colitis(UC) (pancolitis), had an ulcerating rectal tumor. Resection of the rectum and sigmoid colon was performed. Pathology showed an expansive ulcerating adenocarcinoma tumor (type 2) invading the adventitia against a background of UC in a resolving phase. Dysplasia was also found in granular and flat mucosa adjacent to the invading carcinoma. Immunostaining for p53 showed diffuse positivity in both the carcinoma and dysplasia, and also in the mucosa with indefinite dysplasia or no dysplasia neighboring the dysplasia and carcinoma. Mapping of neoplasms and the area with p53 protein overexpression showed that the grade of dysplasia increased as the lesion approached the invasive carcinoma and that the mucosa with dysplasia was surrounded by mucosa without dysplasia or indefinite for dysplasia, but with p53 protein overexpression. In some areas without dysplasia showing p53 overexpression, there was significant morphometric enlargement of the area and diameter of the nucleus p53 Immunostaing is a good marker for assessing the genetic alterations that precede histological abnormalities and for diagnosing carcinoma in UC. Objective findings such as p53-protein overexpression and morphometric values should be used to evaluate cytological abnormalities in UC, as well as in common colorectal cancer.
Similar content being viewed by others
References
Goldgraber MB, Kirsner JB. Carcinoma of the colon in ulcerative colitis. Cancer 1964;17:657–665.
Katza I, Brady RS, Morris E, et al. Assessment of colorectal cancer risk in patients with ulcerative colitis: Experience from a private practice. Gastroenterology 1983;85:22–29.
Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardised classification with provisional clinical applications. Hum Pathol 1983;14:931–968.
Derroede GJ, Taylor WF, Sauer WG. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285:17–21.
Morson BC, Pang SC. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 1962;8:423–434.
Fuson JA, Farmer RG, Hawk WA, et al. Endoscopic surveillance for cancer in chronic ulcerative colitis. Am J Gastroenterol 1980;73:120–126.
Hulten L, Kewenter J, Ahren C. Precancer and carcinoma in chronic ulcerative colitis: A histopathological and clinical investigation. Scand J Gastroenterol 1972;7:663–669.
Cook MG, Goligher JC. Carcinoma and epithelial dysplasia complicating ulcerative colitis. Gastroenterology 1975;68:1127–1136.
Fenoglio CM, Pascal RR. Adenomatous epithelium, intraepithelial anaplasia, and invasive carcinoma in ulcerative colitis. Am J Dig Dis 1973;18:558–562.
Gewertz BL, Dent TL, Appelman HD. Implications of precancerous rectal biopsy in patients with inflammatory bowel disease. Arch Surg 1976;111:326–329.
Nugent FW, Haggitt RC, Colcher H, et al. Malignant potential of chronic ulcerative colitis: Preliminary report. Gastroenterology 1979;76:1–5.
Yardley JH, Keren DF. “Precancer” lesions in ulcerative colitis: A retrospective study of rectal biopsy and colectomy specimens. Cancer 1974;34:835–844.
Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer in colitis: Assessment of the individual risk by clinical and histological criteria. Gastroenterology 1977;73:1280–1289.
Blackstone MO, Riddell RH, Rogers BHG, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: An indication for colectomy. Gastroenterology 1981;80:366–374.
Dobbins WO III. Current status of the precancer lesion in ulcerative colitis. Gastroenterology 1977;73:1431–1433.
Myrvold HE, Kock NG, Ahren C. Rectal biopsy and precancer in ulcerative colitis. Gut 1974;15:301–304.
Watanabe H, Ajioka Y, Kobayashi M, et al. Early colorectal cancer and molecular biology (in Japanese). I to Cho (Stomach Intestine) 1994;29:171–180.
Nishikura K, Watanabe H, Kato N. Gatric microcarcinoma: Its histoligical varieties and differential diagnosis (in Japanese). I to cho (Stomach and Intestine) 1995;30:1295–1307.
Oohashi Y, Watanabe H, Ajioka Y, et al. p53 Immunostaining distinguishes malignant from benign lesions of the gallbladder. Pathol Int 1995;45:58–65.
Matsuda K, Watanabe H, Ajioka Y, et al. Ulcerative colitis and colon cancer (in Japanese). Mol Med 1995;32:1158–1168.
Matsuda K, Watanabe H, Jass JR, et al. Incidence of p53-positive cells is different among histological phases of ulcerative colitis. Acta Med Biol 1995;43:197–203.
Kobayashi M, Watanabe H, Ajioka Y, et al. Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Arch [A] 1995;427:27–32.
Kobayashi M, Watanabe H, Ajioka Y, et al. Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers; relationship to distribution of proliferating cells. Hum Pathol (in press).
Watanabe H, Ajioka Y, Yamaguchi M, et al. New histological criteria of colorectal adenoma and carcinoma (in Japanese). I to Cho (Stomach and Intestine). 1989;24:253–259.
Katagiri K, Watanabe H, Ajioka Y, et al. Importance of grading of cytologic atypia for well differentiated adenocarcinoma of the colorectum (in Japanese). I to Cho (Stomach and Intestine) 1994;29:841–849.
Ajioka Y, Watanabe H, Kobayashi M, et al. Ulcerative colitis-associated dysplasia and carcinoma: With special reference to their macroscopic and stereomicroscopic characteristics and histological diagnosis (in Japanese). I to Cho (Stomach and Intestine) 1995;30:629–642.
Japanese Research Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Jpn J Surg 1983;13:557–573.
Watanabe H, Jass JR, Sobin LH. Histological typing of oesophageal and gastric tumours. 2nd ed. New York Berlin Heidelberg Tokyo: Springer, 1990:23.
Lewin KJ, Riddell RH, Weinstein WM. Gastrointestinal pathology and its clinical implications, vol 2. New York: Igaku-Shoin, 1992:929–949.
Pascal RR. Consistency in the terminology of colorectal dysplasia. Hum Pathol 1988;19:1249–1250.
Pascal RR. Dysplasia and early carcinoma in inflammatory bowel disease and colorectal adenomas. Hum Pathol 1994;25:1160–1171.
Matsuda K, Watanabe H, Ajioka Y, et al. Diagnosis and treatment of colorectal microcarcinoma measuring 5 mm or less (in Japanese). I to Cho (Stomach and Intestine). 1995;30:1551–1564.
Campo E, Calle-Martin O, Miquel R et al. Loss of heterozygosity of p53 gene and p53 protein in human colorectal carcinomas. Cancer Res 1991;51:4436–4442.
Rodrigues NR, Rowan A, Smith MEF, et al. p53 Mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555–7559.
Purdie CA, O'Grady J, Piris J, et al. p53 expression in colorectal tumors. Am J Pathol 1991;138:807–813.
Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675–679.
Baas IO, Mulder JWR, Offerhaus GJA, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5–12.
Taylor HW, Boyle M, Smith SC, et al. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg 1993;80:442–444.
Chaubert P, Benhatttar J, Saraga E, Costa J. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol 1994;144:767–775.
Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71–74.
Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934–944.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsuda, K., Watanabe, H., Ajioka, Y. et al. Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium. J Gastroenterol 31, 860–867 (1996). https://doi.org/10.1007/BF02358616
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02358616